Audi and Krajete aim at create sustainable next-generation technologies. © AUDI AG

Automotive company Audi AG and gas fermentation specialist Krajete GmbH are building a highly effective industrial-scale CO2 Direct Air Capturing plant in Linz.

Solein protein powder. © Solar Foods

Finnish Solar Foods Ltd has got the first ever novel food authorisation for its microbially-produced protein powder Solein.

In 2020, Catalent took over Bone Therapeutics' tcell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA, including all of its assets located in Gosselies, Belgium. © Bone Therapeutics

Bone Therapeutics has merged with French inflammatory/autoimmune company Medsenic in a €40m deal and changed its name into BioSenic.

 

© Resolve Biosciences

Molecular cartography company Resolve Biosciences has raised $71m in series B funding co-led by Patient Square Capital, EDBI, Alafi Capital and NRW.BANK as well as other existing investors.

© Peter Fraser

Cambridge-based Enhanc3D Genomics Ltd has raised £10m in Series A financing led by BGF and Parkwalk Advisors.

Univercells SA

Belgian CDMO Univercells SA has raised €44m through the first close of its Series D financing round led by Belgian and international investors. I

Patients with emerging sepsis can be stratified on the basis of blood concentrations of bio-ADM. © Spingotec GmbH

German Adrenomed AG has got a recommendation from the EMA to push its Adrenomedullin-binding antibody Adrecizumab into a pivotal Phase III study.

pixabay.com/eco_pramono

Mablink Bioscience has baged €31m in a Series A round led by Sofinnova Partners and Mérieux Equity Partners to speed up its pipeline of ADCs.

The experts of the "Energy" panel (from right: Moderator Derrick Williams), Prof. Thomas Brück (TUM), David Hampton (Pheide AG), Dr Alexander Krajete (Krajete GmbH), Juliana Rolf (Münster University of Applied Sciences) and Dr Volker Bauer (LXP Group, not in the picture). © BIOCOM AG

Industry experts have presented the latest biotech solutions for tackling climate change at the first INDUSTRIA BIOTEC conference, Europe’s new forum for the industrial biotech sector.

Stalicla CEO Lynn Durham at BIO. © BIO

Precision neuroscience company Stalicla SA has licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia.